Arizona State Retirement System increased its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 5.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,425 shares of the biopharmaceutical company’s stock after buying an additional 1,538 shares during the period. Arizona State Retirement System’s holdings in Dynavax Technologies were worth $351,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Signaturefd LLC raised its stake in Dynavax Technologies by 12,690.7% in the first quarter. Signaturefd LLC now owns 5,500 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 5,457 shares in the last quarter. Sheaff Brock Investment Advisors LLC purchased a new stake in Dynavax Technologies in the fourth quarter worth about $151,000. Raymond James & Associates purchased a new stake in Dynavax Technologies in the fourth quarter worth about $153,000. Private Advisor Group LLC purchased a new stake in Dynavax Technologies in the fourth quarter worth about $161,000. Finally, Ingalls & Snyder LLC grew its holdings in Dynavax Technologies by 24.0% in the fourth quarter. Ingalls & Snyder LLC now owns 15,500 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 3,000 shares during the period. 76.80% of the stock is owned by institutional investors.
In other news, insider Justin Burgess sold 6,000 shares of the stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $10.00, for a total transaction of $60,000.00. Following the sale, the insider now owns 3,854 shares in the company, valued at $38,540. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 9.31% of the company’s stock.
Dynavax Technologies Price Performance
Dynavax Technologies (NASDAQ:DVAX – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.02). Dynavax Technologies had a net margin of 23.12% and a return on equity of 87.36%. The firm had revenue of $113.99 million for the quarter, compared to analysts’ expectations of $117.76 million. During the same quarter in the previous year, the company earned $0.01 EPS. Analysts anticipate that Dynavax Technologies Co. will post 1.15 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Dynavax Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $23.50.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
- Get a free copy of the StockNews.com research report on Dynavax Technologies (DVAX)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.